Literature DB >> 6367570

Lack of relationship between hepatic toxicity and acetylator phenotype in three thousand South Indian patients during treatment with isoniazid for tuberculosis.

P Gurumurthy, M S Krishnamurthy, O Nazareth, R Parthasarathy, G R Sarma, P R Somasundaram, S P Tripathy, G A Ellard.   

Abstract

The results are presented of a retrospective analysis of the incidence of jaundice among 3,000 patients with pulmonary tuberculosis and of the activities of serum aspartate aminotransferase among 850 according to their isoniazid acetylator phenotype. The patients had been treated with a variety of isoniazid-containing regimens in a series of controlled clinical trials in South India. The results show that rapid acetylators are no more prone to develop isoniazid-induced hepatic toxicity than are slow acetylators.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6367570     DOI: 10.1164/arrd.1984.129.1.58

Source DB:  PubMed          Journal:  Am Rev Respir Dis        ISSN: 0003-0805


  22 in total

Review 1.  Idiosyncratic drug-induced liver injury and the role of inflammatory stress with an emphasis on an animal model of trovafloxacin hepatotoxicity.

Authors:  Patrick J Shaw; Patricia E Ganey; Robert A Roth
Journal:  Toxicol Sci       Date:  2010-06-10       Impact factor: 4.849

Review 2.  Ethnic differences in drug disposition and responsiveness.

Authors:  A J Wood; H H Zhou
Journal:  Clin Pharmacokinet       Date:  1991-05       Impact factor: 6.447

3.  Risk Factors of Hepatotoxicity During Anti-tuberculosis Treatment.

Authors:  A C Anand; A K Seth; M Paul; P Puri
Journal:  Med J Armed Forces India       Date:  2011-07-21

4.  CYP2E1 genotype and isoniazid-induced hepatotoxicity in patients treated for latent tuberculosis.

Authors:  Nicolas Vuilleumier; Michel F Rossier; Alberto Chiappe; Florence Degoumois; Pierre Dayer; Bernadette Mermillod; Laurent Nicod; Jules Desmeules; Denis Hochstrasser
Journal:  Eur J Clin Pharmacol       Date:  2006-04-27       Impact factor: 2.953

Review 5.  Hepatotoxicity of antitubercular treatments. Rationale for monitoring liver status.

Authors:  F Durand; G Jebrak; D Pessayre; M Fournier; J Bernuau
Journal:  Drug Saf       Date:  1996-12       Impact factor: 5.606

Review 6.  Pharmacokinetic factors in the modern drug treatment of tuberculosis.

Authors:  J G Douglas; M J McLeod
Journal:  Clin Pharmacokinet       Date:  1999-08       Impact factor: 6.447

7.  Clinical and biochemical profile of tuberculosis in patients with liver cirrhosis.

Authors:  Praveen Sharma; Pankaj Tyagi; Vikas Singla; Naresh Bansal; Ashish Kumar; Anil Arora
Journal:  J Clin Exp Hepatol       Date:  2015-01-27

8.  Antituberculosis treatment-induced hepatotoxicity: role of predictive factors.

Authors:  J Singh; A Arora; P K Garg; V S Thakur; J N Pande; R K Tandon
Journal:  Postgrad Med J       Date:  1995-06       Impact factor: 2.401

9.  Fatal isoniazid-induced hepatitis. Its risk during chemoprophylaxis.

Authors:  S R Salpeter
Journal:  West J Med       Date:  1993-11

10.  Protective effects of kaempferol on isoniazid- and rifampicin-induced hepatotoxicity.

Authors:  Tung-Yuan Shih; Ton-Ho Young; Herng-Sheng Lee; Chung-Bao Hsieh; Oliver Yoa-Pu Hu
Journal:  AAPS J       Date:  2013-04-17       Impact factor: 4.009

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.